An Ep-ICD Based Index Is a Marker of Aggressiveness and Poor Prognosis in Thyroid Carcinoma

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  He, Helen C H ^a   Kashat, Lawrence ^a   Kak, Ipshita ^a   Kunavisarut, Tada ^a   Gundelach, Raefe ^a,b   Kim, Dae ^a,b   So, Anthony K C ^a   MacMillan, Christina ^a   Freeman, Jeremy L ^a,b   Ralhan, Ranju ^a,b,c   Walfish, Paul G ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE EXTRACELLULAR DOMAIN; EPITHELIAL CELL ADHESION MOLECULE INTRACELLULAR DOMAIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EPITHELIAL CELL ADHESION MOLECULE SUBCELLULAR LOCALIZATION INDEX SCORE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THYROID PAPILLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AREA UNDER CURVE; CARCINOMA; CELL ADHESION MOLECULES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; RESEARCH DESIGN; ROC CURVE; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866716782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042893     Document Type: Article

References (33)

1. Cimino A, Halushka M, Illei P, Wu X, Sukumar S, et al. (2009) Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat.
2. Raffel A, Eisenberger CF, Cupisti K, Schott M, Baldus SE, et al. (2010) Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol 162: 391-398.
3. El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, et al. (2010) Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther 9: 57-66.
4. Weismann P, Weismanova E, Masak L, Mlada K, Keder D, et al. (2009) The detection of circulating tumor cells expressing E6/E7 HR-HPV oncogenes in peripheral blood in cervical cancer patients after radical hysterectomy. Neoplasma 56: 230-238.
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
8. Trzpis M, Bremer E, McLaughlin PM, de Leij LF, Harmsen MC, (2008) EpCAM in morphogenesis. Front Biosci 13: 5050-5055.
9. Stingl J, Eaves CJ, Zandieh I, Emerman JT, (2001) Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res Treat 67: 93-109.
10. Shan YF, Huang YL, Xie YK, Tan YH, Chen BC, et al. (2010) Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status. Med Oncol.
11. Maetzel D, Denzel S, Mack B, Canis M, Went P, et al. (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11: 162-171.
12. Patriarca C, Macchi RM, Marschner AK, Mellstedt H (2011) Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat Rev.
13. van der Gun BTF, Melchers LJ, Ruiters MHJ, de Leij LFMH, McLaughlin PMJ, et al. (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913-1921.
14. Ralhan R, Cao J, Lim T, Macmillan C, Freeman JL, et al. (2010) EpCAM nuclear localization identifies aggressive Thyroid Cancer and is a marker for poor prognosis. BMC Cancer 10: 331.
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
16. Sipos JA, Mazzaferri EL, (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22: 395-404.
17. Lin JD, Hsueh C, Chao TC, (2009) Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid 19: 1053-1059.
18. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC, (2007) EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 96: 1013-1019.
19. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, et al. (2008) Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 7: 1162-1173.
20. Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, et al. (2012) EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene.
21. Ciampi R, Nikiforov YE, (2005) Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16: 163-172.
22. Ghossein R, (2009) Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch Pathol Lab Med 133: 683-691.
23. Nikiforov YE, Nikiforova MN, (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7: 569-580.
24. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, et al. (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 30: 3153-3162.
25. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, et al. (2001) Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129: 552-558.
26. Jo YS, Li S, Song JH, Kwon KH, Lee JC, et al. (2006) Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91: 3667-3670.
27. Cibas ES, Ali SZ, (2009) The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 19: 1159-1165.
28. Moses W, Weng J, Sansano I, Peng M, Khanafshar E, et al. (2010) Molecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine-needle Aspiration Biopsy. World Journal of Surgery 34: 2589-2594.
29. Ohori NP, Nikiforova MN, Schoedel KE, LeBeau SO, Hodak SP, et al. (2010) Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathology 118: 17-23.
30. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, et al. (2010) Impact of Proto-Oncogene Mutation Detection in Cytological Specimens from Thyroid Nodules Improves the Diagnostic Accuracy of Cytology. Journal of Clinical Endocrinology & Metabolism 95: 1365-1369.
31. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, et al. (2005) Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 12: 305-317.
32. Fadda G, Rossi ED, Raffaelli M, Pontecorvi A, Sioletic S, et al. (2011) Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol 165: 447-453.
33. Cochand-Priollet B, Dahan H, Laloi-Michelin M, Polivka M, Saada M, et al. (2011) Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid 21: 1067-1073.